AN2 Therapeutics, Inc. 10-K filing
Filed 2026-03-17 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001193125-26-110693
- Form type
- 10-K
- CIK
- 0001880438
- Primary document
- https://www.sec.gov/Archives/edgar/data/1880438/000119312526110693/antx-20251231.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for AN2 Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-38.1M | - | - |
| Net Income | $-35.2M | - | - |
| Eps Basic | -1.16 | - | - |
| Eps Diluted | -1.16 | - | - |
| Cash And Equivalents | $19.9M | - | - |
| Total Assets | $62.0M | - | - |
| Total Liabilities | $8.9M | - | - |
| Shareholders Equity | $53.1M | - | - |
| Operating Cash Flow | $-29.8M | - | - |